MEDIC.AT Medicon Hellas S.A.
- Market cap
- EUR 13.7M
- P/E
- 18.2x
- P/B
- -
- ROE
- -
- Dividend yield
- 0.77%
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is MEDIC.AT undervalued?
Graham numberThe Graham number of Medicon Hellas S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medicon Hellas S.A. fundamental analysis
5 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets cannot be compared with the industry.
Profit Consistency 2/2
Profitable for 9 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-16.7%) is below the industry median (14.7%).
Revenue Growth 2/2
Revenue grew 15.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash runway cannot be calculated.
PE vs Market 0/1
PE (18.2x) is above the market median (12.7x).
PE vs Industry 0/1
PE (18.2x) is above the industry median (16.6x).
PBV 0/1
Price to book is negative or not available.
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.8%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 4.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Medicon Hellas S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medicon Hellas S.A.
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It also produces reagents for various analyzers, such as specific protein and hematol…
Full company profileMedicon Hellas S.A. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medicon Hellas S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 11.0M | 11.5M | 13.0M | 12.7M | 13.8M | 13.4M | 15.3M | 21.5M | 20.8M | - |
| Gross Profit | 8.78M | 8.94M | 9.93M | 9.85M | 10.5M | 10.2M | 11.3M | 15.7M | 15.5M | - |
| Operating Income | 1.49M | 2.25M | 2.89M | 1.95M | 2.18M | 1.11M | 1.59M | 5.00M | 3.83M | - |
| Net Income | 699K | 1.67M | 1.17M | 1.72M | 1.83M | 775K | 757K | 3.04M | 2.53M | - |
| EPS | - | - | - | - | - | - | 0.17 | 0.69 | 0.57 | - |
| Balance Sheet | ||||||||||
| Total Assets | 28.7M | 31.0M | 33.0M | 30.7M | 27.2M | 28.5M | 28.6M | 31.2M | 31.8M | - |
| Total Liabilities | 25.1M | 25.7M | 26.9M | 22.8M | 17.5M | 18.3M | 17.6M | 16.8M | 14.9M | - |
| Shareholders' Equity | 3.29M | 4.96M | 6.12M | 7.84M | 9.68M | 10.3M | 11.0M | 14.3M | 17.0M | - |
| Cash & Short-term Investments | 3.16M | 2.39M | 4.04M | 4.42M | 6.22M | 6.07M | 7.20M | 10.4M | 10.2M | - |
| Total Debt | - | - | - | - | 13.5M | 13.8M | 12.6M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.79M | -330K | 1.84M | 4.84M | 3.19M | 1.62M | 3.07M | 4.79M | 1.25M | 525K |
| Capital Expenditure | 223K | 96.0K | 92.4K | 135K | 599K | 1.89M | 735K | 554K | 408K | 1.18M |
| Ratios | ||||||||||
| ROE | 21.3% | 33.8% | 19.0% | 21.9% | 18.9% | 7.6% | 6.9% | 21.2% | 14.9% | - |
| ROA | 2.4% | 5.4% | 3.5% | 5.6% | 6.7% | 2.7% | 2.6% | 9.7% | 8.0% | - |
| Net Profit Margin | 6.3% | 14.6% | 9.0% | 13.5% | 13.3% | 5.8% | 5.0% | 14.1% | 12.2% | - |
| Debt to Equity | - | - | - | - | 1.39x | 1.35x | 1.14x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medicon Hellas S.A. dividends
- Dividend yield
- 0.77%
- Forward dividend
- 0.15 EUR
- Payout ratio
- 4.2%
- Ex-dividend date
- Jul 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | EUR 106K | 0.02 | 4.2% |
| 2021 | EUR 114K | 0.03 | 3.8% |
| 2020 | EUR 114K | 0.03 | 15.1% |
| 2019 | EUR 114K | - | 14.8% |
| 2018 | EUR 114K | - | 6.2% |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 22.03045:21.03045 on Mar 4, 2015.
Who owns Medicon Hellas S.A.
- Insiders 44.74%
- Institutions 0.00%
- Public & others 55.26%
- Shares outstanding 4.42M
Medicon Hellas S.A. company profile
- Company name
- Medicon Hellas S.A.
- Ticker
- MEDIC.AT
- ISIN
- GRS424003002
- Exchange
- Athens Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 180
- Fiscal year end
- December
- Address
- 5-7 Melitona Street, Gerakas, Greece, 153 44
- Phone
- 30 210 66 06 000
- Website
- mediconsa.com
About Medicon Hellas S.A.
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It also produces reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry reagents comprising control and calibration materials, and tests. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications, and supplies IT systems to healthcare providers. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. Medicon Hellas S.A. was founded in 1988 and is headquartered in Gerakas, Greece.
Medicon Hellas S.A. management
4- Mr. Dimotsantos S. SpyridonCEO & Chairman of the Board · born 1947
- Mr. George KyridisChief Financial Officer · born 1963
- Mr. Georgios AntoniouDirector of Sales · born 1972
- Mr. Georgios DimotsantosDeputy CEO & Executive Director · born 1989